A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass

Elliott Bennett-Guerrero*, Hilary P. Grocott, Jerrold H. Levy, Kevin A. Stierer, Charles W. Hogue, Albert T. Cheung, Mark F. Newman, Alison A. Carter, Daniel P. Rossignol, Charles D. Collard

*Corresponding author for this work

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

BACKGROUND: Lipid A, the toxic moiety of endotoxin, is linked to multiple complications after cardiac surgery, including fever, vasodilation, and pulmonary and renal dysfunction. The lipid A antagonist eritoran (or E5564) prevents endotoxin-induced systemic inflammation in animals and humans. In this study we assessed the safety of eritoran administration in patients undergoing cardiac surgery and obtained preliminary efficacy data for the prophylaxis of endotoxin-mediated surgical complications. METHODS: A double-blind, randomized, ascending-dose, placebo-controlled study was conducted at nine hospitals. Patients undergoing coronary artery bypass graft and/or cardiac valvular surgery with cardiopulmonary bypass were enrolled. Patients received a 4-h infusion of placebo (n = 78) vs 2 mg (n = 24), 12 mg (n = 26), or 28 mg (n = 24) of eritoran initiated approximately 1 h before cardiopulmonary bypass. RESULTS: No significant safety concerns were identified with continuous safety monitoring, and enrollment continued to the highest prespecified dose (28 mg). No statistically significant differences were observed in most variables related to systemic inflammation or organ dysfunction/injury. CONCLUSIONS: This Phase II safety study suggests that the administration of the novel lipid A antagonist, eritoran, is not associated with overt toxicity in cardiac surgical patients. Blocking lipid A with eritoran does not appear to confer any clear benefit to elective cardiac surgical patients.

Original languageEnglish (US)
Pages (from-to)378-383
Number of pages6
JournalAnesthesia and Analgesia
Volume104
Issue number2
DOIs
StatePublished - Feb 1 2007

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass'. Together they form a unique fingerprint.

  • Cite this

    Bennett-Guerrero, E., Grocott, H. P., Levy, J. H., Stierer, K. A., Hogue, C. W., Cheung, A. T., Newman, M. F., Carter, A. A., Rossignol, D. P., & Collard, C. D. (2007). A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesthesia and Analgesia, 104(2), 378-383. https://doi.org/10.1213/01.ane.0000253501.07183.2a